… drugs have been approved for the treatment of COVID-19 during the last year, we still do not
… therapeutic strategy to treat immunocompromised patients. Most treatment guidelines are …

… agents have been repurposed as treatment of COVID-19. This article will explore use of …
Likewise, CD4/CD8 ratio, a measure of immune dysfunction, decreased only in participants not …

… participants… COVID-19 in patients with cancer [1], solid organ transplant [2,3], end-stage
renal disease [4,5] and rheumatic immune-mediated diseases on immunosuppressive treatment […

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less frequently …

… treatment groups in immunocompromised participants (LSM difference Day 5: 0.23, 95% CI
– 0.71 to 1.17). Molnupiravir treatment was … in immunocompromised patients with COVID-19. …

… , and hospital or intensive care unit stay in both immunocompromised patients and … that the
immunocompromised participants had a lower risk of achieving seroconversion after covid-19 …

… , patients on immunosuppressive therapy may still receive the COVID-19 vaccine. … participants
in the original study). None of these participants had previously experienced COVID-19 …

… at risk of severe COVID-19 with unsatisfactory responses to … of these treatments among
immunocompromised subjects. … 14 days after treatment administration, eight participants (5.8…

… of COVID-19 randomised clinical trial (RCT) participants. … to immunocompromised patients
in the COVID-19 pandemic … and treatment of COVID-19 in immunocompromised patients was …

… COVID-19 vaccination influences social participation in a prospective, multicenter study with
immunocompromised … of intensive care unit beds occupied by COVID-19 patients to the total …